X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (80) 80
middle aged (63) 63
female (57) 57
male (56) 56
aged (52) 52
adult (51) 51
oncology (45) 45
hematology (39) 39
index medicus (38) 38
antineoplastic combined chemotherapy protocols - therapeutic use (31) 31
aged, 80 and over (25) 25
chemotherapy (24) 24
adolescent (23) 23
treatment outcome (21) 21
cancer (20) 20
lymphomas (19) 19
non-hodgkins-lymphoma (19) 19
rituximab (19) 19
cyclophosphamide - administration & dosage (16) 16
prognosis (16) 16
survival analysis (16) 16
doxorubicin - administration & dosage (15) 15
elderly-patients (14) 14
risk factors (14) 14
young adult (14) 14
antineoplastic combined chemotherapy protocols - administration & dosage (13) 13
antineoplastic combined chemotherapy protocols - adverse effects (12) 12
disease-free survival (12) 12
lymphoma, non-hodgkin - drug therapy (12) 12
recurrence (12) 12
therapy (12) 12
care and treatment (11) 11
lymphoma, large b-cell, diffuse - drug therapy (11) 11
remission induction (11) 11
survival (11) 11
prospective studies (10) 10
retrospective studies (10) 10
trial (10) 10
cyclophosphamide (9) 9
cyclophosphamide - therapeutic use (9) 9
karyotyping (9) 9
life sciences (9) 9
lymphoma (9) 9
neoplasm staging (9) 9
prednisone - administration & dosage (9) 9
survival rate (9) 9
vincristine - administration & dosage (9) 9
antineoplastic agents - therapeutic use (8) 8
clinical trials (8) 8
combined modality therapy (8) 8
disease (8) 8
doxorubicin - therapeutic use (8) 8
drug administration schedule (8) 8
kaplan-meier estimate (8) 8
medicine & public health (8) 8
time factors (8) 8
vindesine - administration & dosage (8) 8
age factors (7) 7
aggressive lymphoma (7) 7
antibodies, monoclonal - administration & dosage (7) 7
antineoplastic agents - administration & dosage (7) 7
bleomycin - administration & dosage (7) 7
bone-marrow transplantation (7) 7
colony-stimulating factor (7) 7
dose-response relationship, drug (7) 7
follow-up studies (7) 7
hemic and lymphatic diseases (7) 7
large-cell lymphoma (7) 7
lymphoma, large b-cell, diffuse - mortality (7) 7
myelodysplastic syndromes - genetics (7) 7
prednisone - therapeutic use (7) 7
salvage therapy (7) 7
transplantation, autologous (7) 7
[ sdv.can ] life sciences [q-bio]/cancer (6) 6
analysis (6) 6
antibodies, monoclonal, murine-derived (6) 6
antineoplastic agents - adverse effects (6) 6
b-cell lymphoma (6) 6
child (6) 6
chop (6) 6
chop chemotherapy (6) 6
europe (6) 6
expression (6) 6
health aspects (6) 6
leukemia, myeloid, acute - genetics (6) 6
lymphoma, large b-cell, diffuse - pathology (6) 6
medical research (6) 6
multicenter (6) 6
multivariate analysis (6) 6
neutropenia (6) 6
neutropenia - chemically induced (6) 6
research (6) 6
risk assessment (6) 6
transplantation (6) 6
abridged index medicus (5) 5
antibodies, monoclonal, murine-derived - administration & dosage (5) 5
antimitotic agents (5) 5
antineoplastic agents (5) 5
bone marrow transplantation (5) 5
bortezomib (5) 5
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal of Clinical Oncology, ISSN 0732-183X, 09/2010, Volume 28, Issue 27, pp. 4184 - 4190
Purpose Salvage chemotherapy followed by high-dose therapy and autologous stem-cell transplantation (ASCT) is the standard treatment for relapsed diffuse large... 
SURVIVAL | PARMA TRIAL | THERAPY | BONE-MARROW TRANSPLANTATION | ONCOLOGY | NON-HODGKINS-LYMPHOMA | CHOP | AGGRESSIVE LYMPHOMA | RANDOMIZED CONTROLLED-TRIAL | CHEMOTHERAPY PLUS RITUXIMAB | ELDERLY-PATIENTS | Recurrence | Humans | Middle Aged | Salvage Therapy | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Transplantation, Autologous | New York City | Stem Cell Transplantation | Young Adult | Time Factors | Lymphoma, Large B-Cell, Diffuse - immunology | Adult | Female | Antigens, CD20 - analysis | Chemotherapy, Adjuvant | Antibodies, Monoclonal, Murine-Derived | Dexamethasone - administration & dosage | Lymphoma, Large B-Cell, Diffuse - drug therapy | Lymphoma, Large B-Cell, Diffuse - surgery | Lymphoma, Large B-Cell, Diffuse - pathology | Risk Assessment | Europe | Risk Factors | Kaplan-Meier Estimate | Proportional Hazards Models | Carboplatin - administration & dosage | Rituximab | Etoposide - administration & dosage | Treatment Outcome | Cytarabine - administration & dosage | Lymphoma, Large B-Cell, Diffuse - mortality | Disease-Free Survival | Ifosfamide - administration & dosage | Antibodies, Monoclonal - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Aged | Israel | Australia | Neoplasm Staging | Bone2 | Original Reports | Hema13 | Clinical Medicine | Medical and Health Sciences | Medicin och hälsovetenskap | MEDICIN | Surgery | Onkologi | Oncology | Cancer and Oncology | Klinisk medicin | MEDICINE | Kirurgi | Cancer och onkologi
Journal Article
LANCET ONCOLOGY, ISSN 1470-2045, 09/2013, Volume 14, Issue 10, pp. 911 - 912
Journal Article
Lancet, The, ISSN 0140-6736, 2016, Volume 388, Issue 10044, pp. 565 - 575
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 12/2012, Volume 30, Issue 36, pp. 4462 - 4469
Journal Article
Clinical Cancer Research, ISSN 1078-0432, 06/2016, Volume 22, Issue 12, pp. 2919 - 2928
Journal Article
British Journal of Haematology, ISSN 0007-1048, 08/2001, Volume 114, Issue 2, pp. 349 - 357
Decitabine (5-aza-2′-deoxycytidine) acts as a powerful demethylating agent in vitro. Clinically, low-dose decitabine ameliorates cytopenias including induction... 
5-azacytidine | monosomy 7 | DNA methyltransferase | decitabine | remission | Decitabine | Remission | Monosomy 7 | 5-Azacytidine | METHYLTRANSFERASE GENE | CELLS | ERYTHROPOIETIN | COLONY-STIMULATING FACTOR | IMMUNODEFICIENCY SYNDROME | ACUTE MYELOID LEUKEMIAS | DEMETHYLATION | ELDERLY PATIENTS | MYELOGENOUS LEUKEMIA | DIFFERENTIATION | HEMATOLOGY | Anemia, Refractory, with Excess of Blasts - mortality | Anemia, Refractory, with Excess of Blasts - genetics | Humans | Leukemia, Myelomonocytic, Chronic - genetics | Middle Aged | Male | Risk | Chromosome Disorders | Leukemia, Myelomonocytic, Chronic - drug therapy | Karyotyping | Anemia, Sideroblastic - mortality | Aged, 80 and over | Adult | Female | Anemia, Refractory - drug therapy | Myelodysplastic Syndromes - drug therapy | Anemia, Refractory, with Excess of Blasts - drug therapy | Drug Administration Schedule | Leukemia, Myelomonocytic, Chronic - mortality | Azacitidine - analogs & derivatives | In Situ Hybridization, Fluorescence | Survival Rate | Anemia, Refractory - mortality | Anemia, Sideroblastic - genetics | Antimetabolites, Antineoplastic - therapeutic use | Chromosome Aberrations | Myelodysplastic Syndromes - mortality | Aged | Myelodysplastic Syndromes - genetics | Anemia, Refractory - genetics | Anemia, Sideroblastic - drug therapy | Azacitidine - therapeutic use
Journal Article
Lancet, The, ISSN 0140-6736, 2011, Volume 378, Issue 9806, pp. 1858 - 1867
Summary Background The outcome of diffuse large B-cell lymphoma has been substantially improved by the addition of the anti-CD20 monoclonal antibody rituximab... 
Internal Medicine | MEDICINE, GENERAL & INTERNAL | MULTICENTER | RESPONSE CRITERIA | AGGRESSIVE LYMPHOMAS | POOR-PROGNOSIS | NON-HODGKINS-LYMPHOMA | REGIMEN | YOUNG-PATIENTS | ELDERLY-PATIENTS | DES-LYMPHOMES | TRANSPLANTATION | Cyclophosphamide - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Prospective Studies | Follow-Up Studies | Humans | Middle Aged | Antibodies, Monoclonal, Murine-Derived - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Cyclophosphamide - adverse effects | Dose-Response Relationship, Drug | Young Adult | Vindesine - adverse effects | Adult | Female | Prednisolone | Doxorubicin - administration & dosage | Severity of Illness Index | Prednisone - administration & dosage | Lymphoma, Large B-Cell, Diffuse - drug therapy | Prednisone - adverse effects | Drug Administration Schedule | Risk Assessment | Rituximab | Treatment Outcome | Bleomycin - administration & dosage | Bleomycin - adverse effects | Vincristine | Lymphoma, Large B-Cell, Diffuse - mortality | Disease-Free Survival | Lymphoma, Large B-Cell, Diffuse - diagnosis | Maximum Tolerated Dose | Adolescent | Survival Analysis | Vindesine - administration & dosage | Doxorubicin - adverse effects | Chemotherapy | Physiological aspects | Lymphomas | B cells | Drug therapy | Methods | Cancer | Dehydrogenases | Toxicity | Population studies | Doxorubicin | Hepatitis | Randomization | Bleomycin | Motivation | Drug dosages | Neutropenia | Cell survival | Hematology | Prednisone | Survival | Patients | Lymphoma | Cyclophosphamide | Lymphocytes B | Monoclonal antibodies | CD20 antigen | Tumors | B-cell lymphoma | Clinical trials | Public speaking | Grants | Clinical medicine | Side effects | lymphoma | survival | International standardization | chemotherapy
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2013, Volume 14, Issue 6, pp. 525 - 533
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 03/2005, Volume 352, Issue 12, pp. 1197 - 1205
Journal Article
Blood, ISSN 0006-4971, 11/2013, Volume 122, Issue 21, pp. 2202 - 2202
Abstract Introduction Anemia is a common feature at diagnosis of patients with lymphoid malignancies and has been previously described as an important... 
Journal Article
Blood, ISSN 0006-4971, 11/2013, Volume 122, Issue 21, pp. 3663 - 3663
Abstract Introduction There are some evidences that blood transfusions, either red blood cell (RBC) or platelet, could impact survival of patients affected... 
Journal Article
Journal Article
by Robak, Tadeusz and Jin, Jie and Pylypenko, Halyna and Verhoef, Gregor and Siritanaratkul, Noppadol and Drach, Johannes and Raderer, Markus and Mayer, Jiri and Pereira, Juliana and Tumyan, Gayane and Okamoto, Rumiko and Nakahara, Susumu and Hu, Peter and Appiani, Carlos and Nemat, Sepideh and Cavalli, Franco and Van Hoof, Achiel and Sheliga, Adriana and Teixeira, Adriana and Tomita, Akihiro and Rocafiguera, Albert Oriol and Suvorov, Alexander and Kuzmin, Alexy and Khojasteh, Ali and Mezlini, Amel and Golenkov, Anatoly and Bosly, Andre and Belch, Andrew and Van De Velde, Ann and Illes, Árpád and Mukhopadhyay, Ashis and Meddeb, Balkis and De Prijck, Bernard and Garichochea, Bernardo and Undar, Bulent and Gabarrón, Caballero and Cao, Carmen and Souza, Carmino and Farber, Charles and Won Suh, Cheol and Burcoveanu, Cristina Ileana and Cebotaru, Cristina Ligia and Truica, Cristina-Ligia and Maruyama, Dai and Belada, David and Ben Yehuda, Dina and Udovitsa, Dmitry and Dolores and Morra, Enrica and Späth-Schwalbe, Ernst and Gonzalez-Barca, Eva and Osmanov, Evgenii and Capote, Francisco Javier and Offner, Fritz and Cardenas, Galvez and Heß, Georg and Manikhas, Georgii and Babu, Govind and Rekhtman, Grigoriy and Rossi, Guiseppe and Marques, Herlander and Marques, Margarida and Bumbea, Horia and Wang, Zhao and Wang, Huaqing and Huang, Huiqiang and Choi, Ilseung and Bulavina, Irina and Lysenko, Irina and Avivi, Irit and Kryachok, Iryna and Zaucha, Jan Maciej and Novak, Jan and Díaz, Joaquín and Demeter, Judit and Alexeeva, Julia and Zhu, Jun and Vilchevskaya, Kateryna and Ishizawa, Kenichi and Mauricio, Kenny and Tobinai, Kensei and Ando, Kiyoshi and Abdulkadryrov, Kudrat and Shih, Lee-Yung and Kuzina, Lyudmila and Gumus, Mahmut and De Wit, Maike and Capra, Marcelo and Golubeva, Marina and Ojeda-Uribe, Mario and Kyselyova, Maryna and Taniwaki, Masafumi and Federico, Massimo and Crump, Michael and Baccarani, Michele and Ogura, Michinori and Egyed, Miklós and Udvardy, Miklos and Kurosawa, Mitsutoshi and Uike, Naokuni and ... and LYM-3002 investigators
The Lancet Oncology, ISSN 1470-2045, 11/2018, Volume 19, Issue 11, pp. 1449 - 1458
In the LYM-3002 study, the efficacy and safety of frontline bortezomib plus rituximab, cyclophosphamide, doxorubicin, and prednisone (VR-CAP) and rituximab,... 
NON-INFERIORITY | TRIAL | 1ST-LINE TREATMENT | IMMUNOCHEMOTHERAPY | MULTICENTER | NETWORK | MANAGEMENT | ONCOLOGY | PLUS RITUXIMAB | GUIDELINES | INDOLENT | Anthracyclines | Cyclophosphamide | Corticosteroids | Bortezomib | Analysis | Prednisone | Steroids
Journal Article